A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Public ClinicalTrials.gov record NCT03517488. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.
Study identification
- NCT ID
- NCT03517488
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 150 participants
Conditions and interventions
Conditions
- Melanoma
- Breast Carcinoma
- Hepatocellular Carcinoma
- Urothelial Carcinoma
- Squamous Cell Carcinoma of the Head and Neck
- Renal Cell Carcinoma
- Colorectal Carcinoma
- Non-small Cell Lung Carcinoma
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Endometrial Carcinoma
- Mesothelioma
- Neuroendocrine Carcinoma
- Cervical Cancer
- Small Cell Lung Carcinoma
- Squamous Cell Carcinoma of the Anus
- Castration-Resistant Prostate Carcinoma
- Nasopharyngeal Carcinoma
- Cholangiocarcinoma
- Basal Cell Carcinoma
- Ovarian Carcinoma
- Fallopian Tube Carcinoma
- Thymoma
- Thymic Carcinoma
- Squamous Cell Carcinoma of the Penis
- Vulvar Carcinoma
- Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy
- Malignant Adnexal Neoplasms
- Non-squamous Cell Salivary Gland Carcinoma
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 10, 2018 (Actual)
- Primary completion
- Jun 1, 2022 (Actual)
- Completion
- Sep 6, 2022 (Actual)
- Last update posted
- Dec 1, 2022
2018 – 2022
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute | Los Angeles | California | 90048 | — |
| UCLA Hematology-Oncology Clinic (Westwood) | Los Angeles | California | 90095 | — |
| University of California San Diego Moores Cancer Center | San Diego | California | 92093-0698 | — |
| University of California San Francisco Medical Center | San Francisco | California | 94115 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| University of Chicago Medicine | Chicago | Illinois | 60637 | — |
| The University of Kansas Clinical Research Center | Fairway | Kansas | 66205 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York | New York | 10016 | — |
| Columbia University Medical Center - Herbert Irving Pavilion | New York | New York | 10032 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of Utah, Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| Emily Couric Clinical Cancer Center | Charlottesville | Virginia | 22903 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03517488, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 1, 2022 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03517488 live on ClinicalTrials.gov.